Booth Bruce

Booth Bruce has demonstrated a pronounced selling bias in recent insider transactions, with no recorded purchases across 84 total trades. The vast majority of activity has centered on two biotech firms: Kymera Therapeutics (KYMR) and Sientra (SION). Bruce’s sales in KYMR have been particularly substantial, including a $6.47 million disposal on March 2, 2026, and a $9.06 million sale the same day. Earlier, between December 10–12, 2025, Bruce executed multiple KYMR sales totaling over $18 million, with single transactions ranging from $9,832 to $8 million. The SION disposals, all dated October 21, 2025, were comparatively smaller but still significant, including a $903,921 sale and several others in the six-figure range. Overall, Bruce’s $51.16 million in lifetime sell-value dwarfs the $1.08 million in buys, with all 25 recent transactions being sales. The concentration in KYMR suggests either a strategic reduction in position or liquidity needs tied to that holding. The absence of any buys since at least October 2025 reinforces a clear divestment trend. While the sales span different magnitudes—from minor dispositions under $10,000 to multimillion-dollar exits—the consistency in direction across both tickers indicates a sustained move away from these positions. No purchases have been reported to offset these sales, leaving no ambiguity about the current dispositional bias.